Clinical Data AstraZeneca lung drug gets ‘surprise’ win in COPD trials BioPharma DiveThe treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.Clinical DataRespiratoryRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) BioPharma Dive The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. Clinical DataRespiratoryRead full story Post navigation Previous: Novartis targets Xolair successor in buyout of startup ExcellergyNext: Otsuka picks up PTSD drug with $700M Transcend buy Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
